scholarly journals Physician Preferences for Botulinum Toxin Injections in Anticoagulated Patients with Spasticity

2016 ◽  
Vol 43 (4) ◽  
pp. 581-583 ◽  
Author(s):  
Adam Kassam ◽  
Chetan P. Phadke ◽  
Farooq Ismail ◽  
Chris Boulias
Keyword(s):  
Botulinum Toxin ◽  
Bleeding Complication ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
International Normalized Ratio ◽  
High Variability ◽  
Complication Rates ◽  
Botulinum Neurotoxin Type A ◽  
Botulinum Toxin Injections ◽  
Anticoagulated Patients

AbstractTo understand physician preferences and bleeding complication rates of intramuscular botulinum neurotoxin type A injections for spasticity management in anticoagulated patients, questionnaires were mailed to 138 physicians across Canada. The international normalized ratio comfort range for injections was <2.0 in 10%, 2.0 to 2.5 in 35%, 2.6 to 3.0 in 25%, and 3.1 to 3.5 in 20% of physicians. Only 23% injected outside their comfort value and 57% did not; 72% did not normalize the international normalized ratio value before injections. Only one injector reported the development of compartment syndrome. As expected, high variability exists in physician preferences in botulinum neurotoxin type A injection in anticoagulated patients.

scholarly journals A Moving Residual Limb: Botulinum Toxin to the Rescue

2020 ◽  
Vol 11 (1) ◽  
pp. 34-37 ◽  
Author(s):  
Marie-Michèle Briand ◽  
Mathieu Boudier-Réveret ◽  
Xavier Rodrigue ◽  
Geneviève Sirois ◽  
Min Cheol Chang
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Neurotoxin ◽  
Rare Complication ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Residual Limb ◽  
Satisfaction Level ◽  
Botulinum Neurotoxin Type A ◽  
Standardized Treatment

AbstractMovement disorders post-amputation are a rare complication and can manifest as the jumping stump phenomenon, a form of peripheral myoclonus. The pathophysiology remains unknown and there is currently no standardized treatment. We describe the case of a 57-year-old male with unremitting stump myoclonus, starting one month after transtibial amputation, in his residual limb without associated phantom or neurological pain. The consequence of the myoclonus was a reduction in prosthetic wearing time. Failure to respond to oral medication led us to attempt the use of botulinum neurotoxin Type A injections in the involved muscles of the residual limb. Injection trials, over a two-year period, resulted in an improvement of movement disorder, an increased prosthetic wearing time and a higher satisfaction level of the patient. Injection of botulinum toxin type A should be considered as an alternative treatment for stump myoclonus to improve prosthetic wearing time and comfort.

scholarly journals Treatment of Immature Scars with Botulinum Toxin

2020 ◽  
pp. 219-226
Author(s):  
Alexandra Chambers
Keyword(s):  
Clinical Practice ◽  
Botulinum Toxin ◽  
Botulinum Neurotoxin ◽  
Biological Effects ◽  
Muscle Tension ◽  
Type A ◽  
Inhibitory Effects ◽  
Botulinum Neurotoxin Type A ◽  
Tissue Healing ◽  
Therapeutic Choice

AbstractUsing Botulinum neurotoxin type A (BoNTA) has yielded promising results in the treatment of immature scars. The biological effects of the toxin on tissue healing appear to be complex and multidimensional and still require additional research. Nevertheless, it is clear that not only does BoNTA reduce muscle tension at the edges of wounds, but it also provides anti-inflammatory effects, promotes angiogenesis and healing, and exerts mediatory or inhibitory effects on a variety of cells. In clinical practice, this pluripotency of BoNTA has been recognized as a therapeutic choice for both prophylaxis and treatment of excessive scarring.

OnabotulinumtoxinA exhibits greater efficacy compared to purified botulinum neurotoxin type A (BoNT/A-150 kDa) in peripheral pain models

Toxicon ◽  
2021 ◽  
Vol 190 ◽  
pp. S70
Author(s):  
Sudhakar R. Subramaniam ◽  
Greg Nicholson ◽  
Brian B. Cai ◽  
Amy D. Brideau-Andersen ◽  
Ron S. Broide
Keyword(s):  
Botulinum Neurotoxin ◽  
Type A ◽  
Botulinum Neurotoxin Type A ◽  
Pain Models ◽  
Peripheral Pain

Real-world treatment intervals with botulinum neurotoxin type A in poststroke spasticity management—Are different formulations different?

Toxicon ◽  
2021 ◽  
Vol 190 ◽  
pp. S63
Author(s):  
Susana Rosa ◽  
Bruno Guimarães ◽  
Joana Martins ◽  
José Luís Mesquita ◽  
Margarida Freitas ◽  
...  
Keyword(s):  
Real World ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Botulinum Neurotoxin Type A

scholarly journals Inhibition of Vesicular Secretion in Both Neuronal and Nonneuronal Cells by a Retargeted Endopeptidase Derivative ofClostridium botulinum Neurotoxin Type A

2000 ◽  
Vol 68 (5) ◽  
pp. 2587-2593 ◽  
Author(s):  
John A. Chaddock ◽  
John R. Purkiss ◽  
Lorna M. Friis ◽  
Janice D. Broadbridge ◽  
Michael J. Duggan ◽  
...  
Keyword(s):  
Neurotransmitter Release ◽  
Botulinum Neurotoxin ◽  
Type A ◽  
Cell Types ◽  
Snare Complex ◽  
Cell Binding ◽  
Vesicle Docking ◽  
Botulinum Neurotoxin Type A ◽  
Clostridial Neurotoxins ◽  
Dose Dependent

ABSTRACT Clostridial neurotoxins potently and specifically inhibit neurotransmitter release in defined cell types by a mechanism that involves cleavage of specific components of the vesicle docking/fusion complex, the SNARE complex. A derivative of the type A neurotoxin fromClostridium botulinum (termed LHN/A) that retains catalytic activity can be prepared by proteolysis. The LHN/A, however, lacks the putative native binding domain (HC) of the neurotoxin and is thus unable to bind to neurons and effect inhibition of neurotransmitter release. Here we report the chemical conjugation of LHN/A to an alternative cell-binding ligand, wheat germ agglutinin (WGA). When applied to a variety of cell lines, including those that are ordinarily resistant to the effects of neurotoxin, WGA-LHN/A conjugate potently inhibits secretory responses in those cells. Inhibition of release is demonstrated to be ligand mediated and dose dependent and to occur via a mechanism involving endopeptidase-dependent cleavage of the natural botulinum neurotoxin type A substrate. These data confirm that the function of the HC domain of C. botulinumneurotoxin type A is limited to binding to cell surface moieties. The data also demonstrate that the endopeptidase and translocation functions of the neurotoxin are effective in a range of cell types, including those of nonneuronal origin. These observations lead to the conclusion that a clostridial endopeptidase conjugate that can be used to investigate SNARE-mediated processes in a variety of cells has been successfully generated.

Sign in / Sign up

Export Citation Format

Share Document